Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis.

Chen-Hua LiuYu-Lueng ShihSheng-Shun YangChih-Lin LinYu-Jen FangPin-Nan ChengChi-Yi ChenCheng-Yuan PengTsai-Yuan HsiehYen-Cheng ChiuTung-Hung SuChun-Jen LiuHung-Chih YangPei-Jer ChenDing-Shinn ChenJia-Horng Kao

Published in: Journal of gastroenterology and hepatology (2019)

Treatment with PrOD for 12 weeks is efficacious and well-tolerated for East Asian non-cirrhotic HCV GT1b patients receiving hemodialysis.

Keyphrases

hepatitis c virus
human immunodeficiency virus
peritoneal dialysis
end stage renal disease
chronic kidney disease
antiretroviral therapy
preterm birth